Clinical Trials Browser

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Kidney Neoplasms, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Cholangiocarcinoma

NCT07174453 2025-12-08

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

Phase 3 Recruiting

192 enrolled

Other solid neoplasm

Solid Tumor Malignancies

NCT03383458 2025-11-21

CheckMate 9DX

Phase 3 Active not recruiting

545 enrolled

Gastrointestinal

Carcinoma, Hepatocellular, Liver Neoplasms

NCT02743494 2025-11-18

CheckMate 577

Phase 3 Completed

794 enrolled 13 charts 2 FDA

Advanced Cancer

NCT03469960 2025-11-18

DICIPLE

Phase 3 Completed

265 enrolled

Thoracic

Non-Small Cell Lung Cancer Metastatic

NCT02477826 2025-10-30

CheckMate 227

Phase 3 Completed

2,747 enrolled 21 charts 3 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03906071 2025-10-21

SAPPHIRE

Phase 3 Completed

577 enrolled 22 charts

Thoracic

Metastatic Non-Squamous Non-Small Cell Lung Cancer

Clinical Trials

LIMITLESS

Nogapendekin Alfa Inbakicept for Advanced Non-Small Cell Lung Cancer

A Study to Compare Chemotherapy Alone Versus Chemotherapy Plus Nivolumab or Nivolumab and BMS-986205, Followed by Continued Therapy After Surgery With Nivolumab or Nivolumab and BMS-986205 in Participants With Muscle Invasive Bladder Cancer

ANVIL

Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer

Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma

EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

SUPRAME

Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2

CheckMate76K

CIME

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial

Beamion LUNG-3: A Study to Test Whether Zongertinib Helps People With Surgically Removed, Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma

Comparing Impact of Treatment Before or After Surgery in Patients With Stage II-IIIB Resectable Non-small Cell Lung Cancer

CheckMate 9DW

STAR-221

eVOLVE-Meso

RELATIVITY1093

MK-6482-043

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma

Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

IMAGINE

eVOLVE-RCC02

CheckMate901

Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma

CheckMate 648

Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer

DREAM3R

A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney Cancer

The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma

RELATIVITY-098

CheckMate 816

Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer

CheckMate 9LA

COMET

FORTITUDE-102

SWE-NEO

Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

CheckMate 9DX

CheckMate 577

DICIPLE

CheckMate 227

SAPPHIRE